Doxylamine Succinate Prices Rebound in August 2026 on Firm US OTC Demand

US import prices for doxylamine succinate retreated slightly firm in the first half of August 2026 after the modest decline recorded in July, with the assessed CFR Los Angeles market expected to strengthen modestly as India ex-netbacks improved and US OTC formulator procurement remained steady ahead of the winter cold-cough season. Doxylamine succinate demand is also benefiting from forward seasonal planning. Early August saw spot assessments recover as buyers moved to replenish stocks and freight-related landed-cost pressure persisted. Mid-month activity was characterized by selective restocking from downstream formulators and West Coast importers building Q3 and early Q4 inventory. Overall, doxylamine succinate moved into a firmer phase, with doxylamine succinate buyers showing greater willingness to secure near-term requirements, although adequate cargo availability limited sharper gains.

Demand patterns provided a clearer base for doxylamine succinate prices in August, while doxylamine succinate procurement strengthened among selected OTC buyers. Pregnancy-care and obstetric applications remained a primary growth driver, with Diclegis, Bonjesta, and generics anchoring prescription demand. Per ChemAnalyst data, pregnancy-care awareness and OTC conversion continue to underpin roughly 4–5% annual demand growth. In parallel, OTC consumer healthcare buyers increased procurement for sleep-aid and cold-cough SKUs, with formulators advancing purchases ahead of the autumn and winter season. Pharmaceutical formulators and private-label manufacturers, including activity noted among Perrigo and Aurobindo USA, replenished selectively, supporting the firmer tone. Distribution channels and major retailers also maintained steady purchasing calendars as buyers prepared for November–February restocking and pre-holiday promotional cycles.

Supply-side dynamics were balanced but less bearish for doxylamine succinate during the first half of August, keeping doxylamine succinate availability comfortable but not sufficiently loose to reverse the firmer sentiment. Indian contract manufacturers continued normal campaign schedules, keeping physical availability adequate while improving export economics supported higher India ex-netbacks. Feedstock pressures remained limited, with aromatic precursor and chlorinated solvent costs broadly stable, although geopolitical risks continued to create upside exposure for oil-linked solvent supply. Logistics remained an important cost factor, particularly across the India–US corridor. Earlier freight increases continued to influence landed costs and procurement decisions, while West Coast importers remained attentive to LA/LB rail dwell and container availability. This combination of steady supply and firmer landed-cost expectations helped prevent a return to the softer July pricing environment.

Looking ahead, CFR Los Angeles prices for doxylamine succinate are expected to firm modestly through early autumn, supported by rising India ex-netbacks, firmer doxylamine succinate replacement costs, and steady US OTC formulator procurement ahead of the winter cold-cough season. ChemAnalyst forecasts indicate modest increases from October, roughly to +0.72%, before softening in November–December at around -0.60% to -0.48%, followed by a rebound of about +1.57% in January 2027. The near-term doxylamine succinate outlook therefore remains constructive, and doxylamine succinate importers are likely to prioritize coverage. The August market is expected to remain supported by seasonal procurement, while adequate doxylamine succinate supply limits aggressive upside. Freight volatility, bunker costs, insurance, geopolitical developments, and changing retail demand remain key variables for the forecast.